{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:22:59Z","timestamp":1789842179030,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T00:00:00Z","timestamp":1548720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T00:00:00Z","timestamp":1548720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immunomodulatory drugs (IMIDs) are very effective in the treatment of multiple myeloma (MM). The description of their cereblon-mediated mechanism of action was a hallmark in MM research. Although the importance of IMID-induced degradation of cereblon-binding proteins is well described in vitro, the prognostic value of their expression levels in MM cells is less clear. Based on recently published data showing somewhat conflicting RNA levels, we analyzed the association between the levels of the Ikaros family zinc finger protein 1 (IKZF1), IKZF3, and karyopherin subunit alpha 2 (KPNA2) proteins measured by flow cytometry and prognostic parameters in 214 newly diagnosed MM patients who were randomized in the GMMG HD6 trial. No statistically significant associations between the expression levels and age, gender, light chain type, International Staging System (ISS) stage or cytogenetic high- and normal risk groups could be identified. Hyperdiploid MM cells expressed significantly higher levels of IKZF1, IKZF3 and KPNA2 than nonhyperdiploid cells. In contrast, translocation t(11;14) was associated with significantly lower expression levels. In conclusion, the observed overexpression of cereblon-binding proteins in MM cells with gain of chromosomes 5, 9, 11, 15, and 19 is consistent with the previously proposed positive regulation of MYC by IKZF1 and IKZF3, as well as MYC activation in hyperdiploid MM cells.<\/jats:p>","DOI":"10.1038\/s41408-019-0174-z","type":"journal-article","created":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T11:03:17Z","timestamp":1548759797000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients"],"prefix":"10.1038","volume":"9","author":[{"given":"Katharina","family":"Kriegsmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Andrea","family":"Baertsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed H. S.","family":"Awwad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Merz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Seckinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Benner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Raab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Hillengass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Bertsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"D\u00fcrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J\u00fcrgen","family":"Salwender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Fenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Munder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hundemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,29]]},"reference":[{"key":"174_CR1","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","volume":"366","author":"A Palumbo","year":"2012","unstructured":"Palumbo, A. et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N. Engl. J. Med. 366, 1759\u20131769 (2012).","journal-title":"N. Engl. J. Med."},{"key":"174_CR2","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa070596","volume":"357","author":"DM Weber","year":"2007","unstructured":"Weber, D. M. et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med. 357, 2133\u20132142 (2007).","journal-title":"N. Engl. J. Med."},{"key":"174_CR3","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","volume":"106","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar, S. V. et al. Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma. Blood 106, 4050\u20134053 (2005).","journal-title":"Blood"},{"key":"174_CR4","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1182\/blood-2015-07-567958","volume":"126","author":"EC Fink","year":"2015","unstructured":"Fink, E. C. & Ebert, B. L. The novel mechanism of lenalidomide activity. Blood 126, 2366\u20132369 (2015).","journal-title":"Blood"},{"key":"174_CR5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kronke","year":"2014","unstructured":"Kronke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301\u2013305 (2014).","journal-title":"Science"},{"key":"174_CR6","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2014","unstructured":"Lu, G. et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343, 305\u2013309 (2014).","journal-title":"Science"},{"key":"174_CR7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature07064","volume":"454","author":"AL Shaffer","year":"2008","unstructured":"Shaffer, A. L. et al. IRF4 addiction in multiple myeloma. Nature 454, 226\u2013231 (2008).","journal-title":"Nature"},{"key":"174_CR8","doi-asserted-by":"publisher","unstructured":"Kronke, J. et al. IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM). Leukemia https:\/\/doi.org\/10.1038\/leu.2016.384 (2017).","DOI":"10.1038\/leu.2016.384"},{"key":"174_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13045-016-0354-2","volume":"9","author":"M Pourabdollah","year":"2016","unstructured":"Pourabdollah, M. et al. High IKZF1\/3 protein expression is a favorable prognostic factor for survival of relapsed\/refractory multiple myeloma patients treated with lenalidomide. J. Hematol. Oncol. 9, 123 (2016).","journal-title":"J. Hematol. Oncol."},{"key":"174_CR10","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1182\/blood-2014-02-557819","volume":"124","author":"YX Zhu","year":"2014","unstructured":"Zhu, Y. X. et al. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood 124, 536\u2013545 (2014).","journal-title":"Blood"},{"key":"174_CR11","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1182\/blood-2014-11-611426","volume":"125","author":"K Sehgal","year":"2015","unstructured":"Sehgal, K. et al. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood 125, 4042\u20134051 (2015).","journal-title":"Blood"},{"key":"174_CR12","doi-asserted-by":"publisher","first-page":"16752","DOI":"10.1074\/jbc.M001551200","volume":"275","author":"CR Kovac","year":"2000","unstructured":"Kovac, C. R., Emelyanov, A., Singh, M., Ashouian, N. & Birshtein, B. K. BSAP (Pax5)-importin alpha 1 (Rch1) interaction identifies a nuclear localization sequence. J. Biol. Chem. 275, 16752\u201316757 (2000).","journal-title":"J. Biol. Chem."},{"key":"174_CR13","doi-asserted-by":"publisher","first-page":"E473","DOI":"10.1002\/ajh.24533","volume":"91","author":"M Merz","year":"2016","unstructured":"Merz, M. et al. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma. Am. J. Hematol. 91, E473\u2013E477 (2016).","journal-title":"Am. J. Hematol."},{"key":"174_CR14","doi-asserted-by":"publisher","unstructured":"Granzow, M. et al. Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis. Haematologica https:\/\/doi.org\/10.3324\/haematol.2016.160721 (2017).","DOI":"10.3324\/haematol.2016.160721"},{"key":"174_CR15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/sj.leu.2403586","volume":"19","author":"S Wuilleme","year":"2005","unstructured":"Wuilleme, S. et al. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia 19, 275\u2013278 (2005).","journal-title":"Leukemia"},{"key":"174_CR16","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1182\/blood-2011-09-379164","volume":"119","author":"K Neben","year":"2012","unstructured":"Neben, K. et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion17p. Blood 119, 940\u2013948 (2012).","journal-title":"Blood"},{"key":"174_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3389\/fimmu.2014.00137","volume":"5","author":"N Robillard","year":"2014","unstructured":"Robillard, N., Wuilleme, S., Moreau, P. & Bene, M. C. Immunophenotype of normal and myelomatous plasma-cell subsets. Front. Immunol. 5, 137 (2014).","journal-title":"Front. Immunol."},{"key":"174_CR18","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3324\/haematol.11080","volume":"93","author":"AC Rawstron","year":"2008","unstructured":"Rawstron, A. C. et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 93, 431\u2013438 (2008).","journal-title":"Haematologica"},{"key":"174_CR19","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1200\/JCO.2016.70.6705","volume":"35","author":"S Robiou du Pont","year":"2017","unstructured":"Robiou du Pont, S. et al. Genomics of multiple myeloma. J. Clin. Oncol. 35, 963\u2013967 (2017).","journal-title":"J. Clin. Oncol."},{"key":"174_CR20","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1182\/blood-2015-06-650242","volume":"126","author":"ML Chretien","year":"2015","unstructured":"Chretien, M. L. et al. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? Blood 126, 2713\u20132719 (2015).","journal-title":"Blood"},{"key":"174_CR21","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1038\/leu.2011.53","volume":"25","author":"WJ Chng","year":"2011","unstructured":"Chng, W. J. et al. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 25, 1026\u20131035 (2011).","journal-title":"Leukemia"},{"key":"174_CR22","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1182\/blood.V128.22.355.355","volume":"128","author":"K Misund","year":"2016","unstructured":"Misund, K. et al. Complementary activation of Ccnd, MYC, RAS and NFkB by mutations in multiple myeloma. Blood 128, 355\u2013355 (2016).","journal-title":"Blood"},{"key":"174_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.66","volume":"5","author":"CC Bjorklund","year":"2015","unstructured":"Bjorklund, C. C. et al. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. Blood Cancer J. 5, e354 (2015).","journal-title":"Blood Cancer J."},{"key":"174_CR24","doi-asserted-by":"publisher","unstructured":"Kuehl, W. M. & Bergsagel, P. L. Early genetic events provide the basis for a clinical classification of multiple myeloma. Hematol. Educ. Prog. 346\u2212352 https:\/\/doi.org\/10.1182\/asheducation-2005.1.346 (2005).","DOI":"10.1182\/asheducation-2005.1.346"},{"key":"174_CR25","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/ajh.24634","volume":"92","author":"A Bolomsky","year":"2017","unstructured":"Bolomsky, A. et al. IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma. Am. J. Hematol. 92, 269\u2013278 (2017).","journal-title":"Am. J. Hematol."},{"key":"174_CR26","doi-asserted-by":"publisher","unstructured":"Dimopoulos, K. et al. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma. Leuk. Lymphoma 1\u22129. https:\/\/doi.org\/10.1080\/10428194.2018.1466290 (2018).","DOI":"10.1080\/10428194.2018.1466290"},{"key":"174_CR27","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1038\/leu.2012.42","volume":"26","author":"B Paiva","year":"2012","unstructured":"Paiva, B. et al. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. Leukemia 26, 1862\u20131869 (2012).","journal-title":"Leukemia"},{"key":"174_CR28","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/j.1365-2141.2005.05849.x","volume":"132","author":"P Moreau","year":"2006","unstructured":"Moreau, P. et al. Lack of CD27 in myeloma delineates different presentation and outcome. Br. J. Haematol. 132, 168\u2013170 (2006).","journal-title":"Br. J. Haematol."},{"key":"174_CR29","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1046\/j.1365-2141.2003.04260.x","volume":"121","author":"JE Guikema","year":"2003","unstructured":"Guikema, J. E. et al. CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease. Br. J. Haematol. 121, 36\u201343 (2003).","journal-title":"Br. J. Haematol."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0174-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0174-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0174-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T16:09:29Z","timestamp":1671206969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0174-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,29]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2]]}},"alternative-id":["174"],"URL":"https:\/\/doi.org\/10.1038\/s41408-019-0174-z","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,29]]},"assertion":[{"value":"31 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.K.: Research Support BMS, Celgene, Sanofi, Morphosys. M.-A.B.: Travel grants: Amgen, Novartis, Bristol-Myers Squibb, Janssen, Sanofi; Honoraria: Novartis, Takeda. M.Merz: Travel grants: Celgene, Takeda, AMGEN, Janssen; Advisory Board: AMGEN; Research grant: Takeda. M.R.: research funding from Novartis, Amgen, Morphosys. J.H.: honoraria from Amgen, BMS, Celgene, Janssen; research support from Sanofi; advisory boards: Amgen, Celegene, Janssen, Novartis. K.W.: advisory board and honoraria: AMGEN, Bristol-Myers Squibb, Celgene, Janssen, Novartis, Takeda, Onyx; research funding: Janssen, Celgene. H.J.S.: honoraria and travel support: Janssen Cilag, Celgene, Bristol Meyer Squibb. M.H.: honoraria Roche, Novartis. R.F.: Honoraria and travel grants: Celgene, Janssen, BMS; research funding: Celgene. M.Munder: Consultancy: Janssen Cilag, BMS, Takeda, Amgen, Celgene. J.D.: advisory Board: Bristol-Myers Squibb, Celgene, Janssen; speakers bureau: Celgene, Janssen; research funding: Celgene. H.G.: Research support: Celgene, Janssen, Chugai, Novartis, BMS; Advisory boards: Janssen, Celgene, Novartis, Amgen, Takeda, BMS; Honoraria: Celgene, Janssen, Novartis, Chugai, BMS. M.H.: Research support: BMS, Celgene, Sanofi, Morphosys. The other authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"13"}}